Thursday, July 17, 2025 7/17/2025

A Uniquely Scalable Approach to Single Cell Sequencing for the Development of Next Generation Cell Therapies

Award Number: R43HG013446
ORGANIZATION: NATIONAL HUMAN GENOME RESEARCH INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 02/23/2024
PERIOD OF PERFORMANCE END DATE: 02/22/2025

Group Awards By:

View Award Description

A Uniquely Scalable Approach to Single Cell Sequencing for the Development of Next Generation Cell Therapies - Immunotherapies (including CAR-T cell therapies) are wonder drugs when they work, but the response rates of today’s immunotherapies are only 15-20% and therapy costs remain prohibitively high for mass adoption. Single-cell sequencing (SC-seq) is becoming the preferred tool for immune profiling to map a patient’s adaptive immune response, and to readout phenotypic changes that result from CRISPR based gene edits at the single cell level. However, the full potential of SC-seq based CRISPR screens and immune repertoire profiling for the development of next generation therapeutics requires a 10-fold to 100-fold increase in cell throughput relative to current platforms. Upcoming expiration of Illumina’s core IP re-ignited competition in US & EU markets. The resulting re-acceleration in the drop of DNA sequencing costs (6-fold price reduction in 2023 vs. Illumina’s 2022 pricing) makes SC-seq of 10 million cells affordable today (20-30 million cells in ~3 years and 100 million cells in 6 years), but existing methods for SC-seq do not support throughput beyond 1 million cells per experiment. Proposed alternatives are scalable, but trade-offs in performance and ease-of-use make them unsuitable for translational research. Sansimeon’s approach uniquely scales SC-seq with throughput >100M cells, while retaining the ease-of-use and necessary cell capture efficiency for high-throughput applications in translational research. Our platform incorporates a technology for in-line sample debulking, which was previously commercialized for applications in cell therapy manufacturing and rare cell isolation. Sansimeon’s ability to sequence >100 million single cells directly from crude & complex samples (such as whole blood or bone marrow aspirates), with a single-step automated workflow, makes the platform ideally suited for high-throughput applications in translational research.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2024 ( Subtotal = $399,369 )
2024	2024	SANSIMEON INC	1209 N ORANGE ST	WILMINGTON	DE	19801	NEW CASTLE	USA	Human Genome Research	000	1	2/23/2024	NEW	$399,369
														Subtotal = $399,369

Grand Total All Awards = $399,369

Top

All Categories

About

Search

Reports

Data Submission

Award Information

A Uniquely Scalable Approach to Single Cell Sequencing for the Development of Next Generation Cell Therapies

Award Number: R43HG013446

ORGANIZATION: NATIONAL HUMAN GENOME RESEARCH INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 02/23/2024

PERIOD OF PERFORMANCE END DATE: 02/22/2025

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer